Back to Newsroom

Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis

NORWOOD, MA — (Marketwired) — 11/29/16 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it is commencing a one-year, open-label extension study of the ongoing Phase 2 clinical study of Resunab (“JBT-101”) for the treatment of skin-predominant dermatomyositis. This open-label extension was submitted to and reviewed by the U.S. Food and Drug Administration (“FDA”).

Click here to read the full release